Clinical and prognostic significance of pathological reclassification in ovarian neuroendocrine tumors: a retrospective study (O-NET study)
Not Applicable
- Conditions
- Primary ovarian neuroendocrine tumors
- Registration Number
- JPRN-UMIN000019754
- Lead Sponsor
- Kansai Clinical Oncology Group - Gynecologic Cancer Group -
- Brief Summary
Of the 68 enrolled patients, 48 were eligible for analysis. All carcinoids (n = 32) were reclassified as NET G1/G2, whereas 14 of 16 carcinomas were reclassified as NEC/mixed adeno-NEC (MANEC) (Fisher exact test; p < 0.01). The OS/PFS was 49.0/42.5 months and 6.5/3.9 months for NET G1/G2 and NEC/MANEC, respectively. Histology revealed that NEC/MANEC was associated with increased risk of death (HR = 48.0; 95% CI, 3.93-586; p < 0.01) and disease progression (HR = 51.6; 95% CI, 5.54-480; p < 0.01).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 48
Inclusion Criteria
Not provided
Exclusion Criteria
Multiple malignancies within five years.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Overall survival time
- Secondary Outcome Measures
Name Time Method Progression free survival time